ライフサイエンスコーパス: stem cell transplant

1 h high-dose melphalan therapy and autologous stem cell transplant.

2 the development of allogeneic hematopoietic stem cell transplant.

3 0(9) engineered T cells 2 d after autologous stem cell transplant.

4 titution after unrelated-donor hematopoietic stem cell transplant.

5 Hodgkin lymphoma received chemotherapy and a stem cell transplant.

6 ailed to identify an etiology, 6 weeks after stem cell transplant.

7 sion-free without a consolidative allogeneic stem cell transplant.

8 tezomib treatment and high-dose melphalan in stem cell transplant.

9 and mortality after allogeneic hematopoietic stem cell transplant.

10 espite resection or allogeneic hematopoietic stem cell transplant.

11 and mortality after allogeneic hematopoietic stem cell transplant.

12 olidation in first remission with autologous stem cell transplant.

13 tivation is a significant complication after stem cell transplant.

14 ith one of these viruses after hematopoietic stem cell transplant.

15 p select appropriate patients for allogeneic stem cell transplant.

16 ections occur frequently after hematopoietic stem cell transplant.

17 ole without recurrence after a hematopoietic stem cell transplant.

18 utility and convenience of peripheral blood stem cell transplant.

19 se of pneumonia following a peripheral blood stem cell transplant.

20 ) in those who had undergone a hematopoietic stem cell transplant.

21 emotherapy in combination with hematopoietic stem cell transplant.

22 eatment for primary disease is hematopoietic stem cell transplant.

23 35 (53%) to lenalidomide; 39 (59%) had prior stem cell transplant.

24 .2) in those who had undergone hematopoietic stem cell transplant.

25 mia treatment that included an HIV-resistant stem cell transplant.

26 latinum-based chemotherapy before autologous stem cell transplant.

27 4 consecutive patients undergoing allogeneic stem cell transplant.

28 opoietic progenitor cells in preparation for stem cell transplant.

29 tological malignancies and the recipients of stem-cell transplant.

30 enance treatment or autologous or allogeneic stem-cell transplant.

31 onders proceeding to a subsequent allogeneic stem-cell transplant.

32 n age at cancer diagnosis and haematopoietic stem-cell transplant.

33 py, prior methotrexate, and prior autologous stem-cell transplant.

34 atments (range 1-11); 18 (38%) had undergone stem-cell transplant.

35 6 responses among the 18 patients with prior stem-cell transplant.

36 ease (>/=10(-4) cells) received an allogenic stem-cell transplant.

37 ho were not planned for immediate autologous stem-cell transplant.

38 osuppressive therapies and/or solid organ or stem cell transplants.

39 rance to both solid organ and haematopoietic stem cell transplants.

40 with human lymphoid tissue and hematopoietic stem cell transplants.

41 has become the preferred source of HSPCs for stem cell transplants.

42 oxantrone, or with autologous haematopoeitic stem cell transplants.

43 iduals, particularly those who have received stem cell transplants.

44 versus host disease in matched or mismatched stem cell transplants.

45 may reduce the rate of relapse in allogeneic stem cell transplants.

46 nalidomide), and 76% had received autologous stem-cell transplants.

47 constitution in recipients of haploidentical stem-cell transplants.

48 Which patients should receive an allogeneic stem cell transplant?

49 (18%) patients had relapsed after allogeneic stem-cell transplants, 13 (76%) had previously received

50 th noncrystalline LCPT, of whom 11 underwent stem cell transplant, 16 received chemotherapy only, and

51 compared with patients who did not receive a stem-cell transplant (42% v 16%).

52 a who had undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier.

53 ew and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and um

54 could guide migration and differentiation of stem cell transplants after brain injury.

55 se starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the

56 jor complication of allogeneic hematopoietic stem cell transplant (alloHSCT), underscoring the need t

57 ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good re

58 complication among allogeneic hematopoietic stem cell transplant (alloSCT) recipients.

59 uSCT) and poor-risk patients (PR) allogeneic stem cell transplant (AlloSCT).

60 Stem cell transplant ameliorated clinical symptoms in on

61 ving mobilized stem cells all accepted their stem cell transplant and became tolerant to the VCA.

62 Risk-adapted stem cell transplant and consolidation with novel agents

63 patients in need of allogeneic hematopoietic stem cell transplant and has recruited millions of volun

64 tients (P = .005 vs allogeneic hematopoietic stem cell transplant and P = .048 vs others).

65 ollowed by high-dose therapy with autologous stem cell transplant and subsequent antidisialogangliosi

66 al infections that occur after hematopoietic stem cell transplant and therapies for hematologic malig

67 plant, persons with autologous hematopoietic stem cell transplant and those without graft-versus-host

68 tegies such as unrelated donor hematopoietic stem cell transplant and tyrosine kinase inhibitors into

69 of an additional 300 patients who underwent stem cell transplant and were enrolled on multicentre cl

70 Four of the children received hematopoietic stem cell transplants and all showed poor graft function

71 By overcoming the limitations of stem cell transplants and better understanding the mecha

72 , and biologic therapy such as hematopoietic stem cell transplants and mesenchymal cell infusions.

73 eived consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients

74 Studies of critically ill, oncologic or stem cell transplant, and solid organ transplant patient

75 sed immunosuppressive drugs, 13 had received stem cell transplants, and 7 were infected with human im

76 e transfusions, bone marrow or hematopoietic stem cell transplants, and experimental pharmacologic ch

77 ey, liver, bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfusion.

78 Recipients of allogeneic hematopoietic stem cell transplant appear to have the highest risk of

79 icacy for both solid organ and hematopoietic stem cell transplant applications.

80 Autologous bone marrow and stem-cell transplant approaches in lymphoma patients hav

81 recipients of a solid organ or hematopoietic stem cell transplant are living longer with a better qua

82 in the field of hematology, as hematopoietic stem cell transplants are already commonplace in clinics

83 The majority of allogeneic stem cell transplants are currently undertaken using G-C

84 t of genetically corrected autologous airway stem cell transplant as a treatment for CF.

85 ositron emission tomography or hematopoietic stem cell transplant as independent prognostic factors f

86 damine-ferumoxytol-positive macrophages into stem cell transplants, as visualized with IVM and histop

87 In addition, pre-autologous stem cell transplant (ASCT) (18)FDG-PET response to SLT

88 ated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulato

89 5 patients initially treated with autologous stem cell transplant (ASCT) at Mayo Clinic.

90 ne (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with IV busulfan

91 ial, addition of 211At-CD38 to an autologous stem cell transplant (ASCT) conditioning regimen may imp

92 Utilization of autologous stem cell transplant (ASCT) was similar across all perio

93 des salvage chemotherapy (SC) and autologous stem cell transplant (ASCT).

94 High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative t

95 refractory myeloma undergoing an autologous stem-cell transplant (ASCT).

96 luding cytarabine, rituximab, and autologous stem-cell transplant (ASCT).

97 -melphalan with low-dose TBI after haplocord stem cell transplant assures good engraftment and leads

98 isk patients (FR) were to receive autologous stem cell transplant (AuSCT) and poor-risk patients (PR)

99 The addition of an autologous stem cell transplant before cART withdrawal alters viral

100 outcomes of patients who underwent haplocord stem cell transplant between May 2013 and March 2015 and

101 Researchers have demonstrated that stem-cell transplants can survive, migrate, differentiat

102 ion for the use of RIC regimens in all adult stem cell transplant candidates with acute leukemia in r

103 bsequent admissions with a non-hematopoietic stem cell transplant cohort and excluded solid-organ tra

104 ted mortality was 32.9% in non-hematopoietic stem cell transplant cohort, which was similar to autolo

105 her when compared with the non-hematopoietic stem cell transplant cohort.

106 (MR) imaging of donor-matched and mismatched stem cell transplants demonstrated decreased signal inte

107 The use of imatinib before stem cell transplant did not have an effect on mortality

108 Allogeneic stem cell transplants differ from conventional tissue tr

109 I, we show that human central nervous system stem cells transplanted either to the neonatal, the adul

110 enced high-dose chemotherapy with autologous stem-cell transplant failure were included.

111 yeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid diffe

112 ion in a patient who received a heterologous stem cell transplant for acquired immunodeficiency syndr

113 t study that examines the role of allogeneic stem cell transplant for adults with acute lymphoblastic

114 sociated with improved outcome to autologous stem cell transplant for NBL.

115 ation provides the benefits of hematopoietic stem cell transplant for nearly all patients who do not

116 old female patient following a hematopoietic stem cell transplant for relapsed acute lymphoblastic le

117 irectly demonstrate the efficacy of myogenic stem cell transplant for treating muscle degenerative di

118 A-deficient SCID (ADA-SCID) is hematopoietic stem cell transplant from an HLA-matched sibling donor,

119 et(high) CTLs) in 53/115 CMV IgG(+) patients stem cell transplanted from CMV IgG(+) donors.

120 ifty-two patients who received hematopoietic stem cell transplants from 2004 through 2008 at the Univ

121 HLA-C2 positive recipients of hematopoietic stem cell transplants from 2DS1 positive donors.

122 ents with AML who had received hematopoietic stem-cell transplants from unrelated donors matched for

123 odysplastic syndrome (MDS) receiving a first stem cell transplant had marrow cells prospectively anal

124 patients with crystalline LCPT treated with stem cell transplant had stable or improved kidney funct

125 ents undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for u

126 Allogeneic hematopoietic stem cell transplant (hazard ratio [HR] = 2.28; 95% conf

127 y results of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and Triplex in hea

128 d as a surveillance method for hematopoietic stem cell transplant (HCT) recipients.

129 t CMV reactivation early after hematopoietic stem cell transplant (HCT).

130 fields of both solid-organ and hematopoietic stem cell transplant (HCT).

131 with CD4(+) </=200; autologous hematopoietic stem-cell transplant (HCT) or allogeneic-HCT recipients.

132 ed in 3 consecutive cohorts of hematopoietic stem-cell transplant (HCT) recipients (n=2049); cohort 1

133 QOL) and symptom burden during hematopoietic stem-cell transplant (HCT).

134 tcome after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relaps

135 herapy and a majority received hematopoietic stem cell transplant (HSCT) (11/13).

136 matched siblings suitable for haematopoietic stem cell transplant (HSCT) are discussed.

137 s among survivors of pediatric hematopoietic stem cell transplant (HSCT) are understudied.

138 bidity and mortality following hematopoietic stem cell transplant (HSCT) because of various hematolog

139 Allogeneic hematopoietic stem cell transplant (HSCT) can be curative, but suitabl

140 Therapeutic hematopoietic stem cell transplant (HSCT) during chronic infection gen

141 ggest potential benefit after haematopoietic stem cell transplant (HSCT) for patients with refractory

142 Autologous hematopoietic stem cell transplant (HSCT) has been effective in treati

143 The field of hematopoietic stem cell transplant (HSCT) has made ground-breaking pro

144 Acute lung injury (ALI) during hematopoietic stem cell transplant (HSCT) is associated with substanti

145 Hematopoietic stem cell transplant (HSCT) is the only cure for sickle

146 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) patients are susceptible to

147 during reactivation of HCMV in hematopoietic stem cell transplant (HSCT) patients soluble Gal-9 is up

148 is in the pediatric allogeneic hematopoietic stem cell transplant (HSCT) population is unknown.

149 a CMV-seronegative allogeneic hematopoietic stem cell transplant (HSCT) recipient is generally accep

150 galovirus (CMV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are typically mon

151 phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received dono

152 ment is a high-risk feature in hematopoietic stem cell transplant (HSCT) recipients with transplant-a

153 etected in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can c

154 ed infectious complications in hematopoietic stem cell transplant (HSCT) recipients.

155 patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients.

156 d mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

157 cal patients and especially in hematopoietic stem cell transplant (HSCT) recipients.

158 to latency and reactivation in hematopoietic stem cell transplant (HSCT) recipients.

159 ty and mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

160 erapy, such as solid organ and hematopoietic stem cell transplant (HSCT) recipients.

161 in patients with leukemia and hematopoietic stem cell transplant (HSCT) recipients.

162 mononuclear cells (PBMCs) from hematopoietic stem cell transplant (HSCT) recipients.

163 lid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

164 ed treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

165 Hematopoietic stem cell transplant (HSCT)-associated thrombotic microa

166 are frequent complications of hematopoietic stem cell transplant (HSCT).

167 cular interest in the field of hematopoietic stem cell transplant (HSCT).

168 olid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT).

169 elated or unrelated allogeneic hematopoietic stem cell transplant (HSCT).

170 a double umbilical cord blood hematopoietic stem cell transplant (HSCT).

171 dystrophy after treatment with hematopoietic stem cell transplant (HSCT).

172 ly when complicating allograft hematopoietic stem cell transplant (HSCT).

173 tabilize cerebral disease is a hematopoietic stem cell transplant (HSCT).

174 and mortality after allogeneic hematopoietic stem cell transplant (HSCT).

175 lable other than myeloablative hematopoietic stem cell transplant (HSCT); however, relapse remains a

176 e infections often occur after hematopoietic stem cell transplant (HSCT); vaccination is important fo

177 tients receiving an allogeneic hematopoietic stem cell transplant (HSCT, 79%) versus those receiving

178 64 admissions for induction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2014 was select

179 infection in adult allogeneic hematopoietic stem-cell transplant (HSCT) patients.

180 ts, the risk of skin cancer in hematopoietic stem-cell transplant (HSCT) recipients has not been exte

181 integration site analysis in a hematopoietic stem cell-transplanted humanized mouse model.

182 Hematopoietic stem cell transplant, if performed early in metachromati

183 an of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were adminis

184 o was cured following a delta32/delta32 CCR5 stem cell transplant in 2007 revealed no antibodies agai

185 t feasible, then high-dose chemotherapy with stem cell transplant in an experienced center is a reaso

186 salvage chemotherapy followed by autologous stem cell transplant in chemosensitive disease.

187 essment; 25 patients underwent an allogeneic stem cell transplant in first CR and were excluded, leav

188 Allogeneic stem cell transplant in second remission is the only cur

189 rther suggests that the rejection of similar stem cell transplants in humans will be dependent upon t

190 of cyclophosphamide (C)-based haploidentical stem-cell transplants indicates that this drug may re-or

191 KIR/HLA mismatched hematopoietic stem cell transplants induce alloreactive NK cells, whic

192 We find that neural stem cells transplanted into the brain after neuronal ab

193 High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disea

194 The role of allogeneic hematopoietic stem cell transplant is less clear but may be useful in

195 In myelofibrosis, stem cell transplant is the current treatment of choice

196 eukemia-like" regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyr

197 8%) had received an allogeneic hematopoietic stem cell transplant (median, 61 [interquartile range {I

198 reg-associated chemokine receptors in murine stem cell transplant models.

199 actory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observatio

200 n = 766; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were

201 CI, 2.39-6.07) and autologous hematopoietic stem cell transplant (odds ratio, 1.28; 95% CI, 1.06-1.5

202 spital mortality in allogeneic hematopoietic stem cell transplant (odds ratio, 3.81; 95% CI, 2.39-6.0

203 choosing between high-dose chemotherapy and stem cell transplant or bortezomib-based chemotherapy.

204 mphoma who previously received an autologous stem cell transplant or two previous multiagent chemothe

205 as a conditioning regimen for hematopoietic stem-cell transplant or myeloablative doses of radioimmu

206 , the conditioning regimen for hematopoietic stem cell transplant (P = .002), and the cumulative dose

207 transplant recipients and one hematopoietic stem-cell transplant patient with positive A. calidoustu

208 We identified all hematologic malignancy and stem cell transplant patients diagnosed with proven muco

209 llowing immune reconstitution, hematopoietic stem cell transplant patients often display reduced immu

210 tality of pediatric cancer and hematopoietic stem cell transplant patients requiring continuous renal

211 , we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing numbers of

212 ssions of pediatric cancer and hematopoietic stem cell transplant patients, 68 of 70 evaluable patien

213 In a longitudinal study of hematopoietic stem cell transplant patients, bone marrow- and liver-en

214 cipients of solid organ transplantation, and stem cell transplant patients, emphasizing the parallels

215 setting and in solid-organ and hematopoietic stem cell transplant patients.

216 her odds of mortality than non-hematopoietic stem cell transplant patients.

217 significantly higher than non-hematopoietic stem cell transplant patients.

218 cation in pediatric cancer and hematopoietic stem cell transplant patients.

219 megalovirus (CMV) infection in hematopoietic stem cell transplant patients.

220 cluding patients who received blood-building stem cell transplants, patients with chronic granulomato

221 om 663 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007 for tr

222 Among patients with hematopoietic stem cell transplant, persons with autologous hematopoie

223 lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of

224 myelodysplastic syndromes, and hematopoietic stem cell transplant populations has been evaluated in r

225 x is a promising biomaterial for delivery of stem cell transplant populations, with no adverse effect

226 of Legionnaires' disease in a hematopoietic stem cell transplant recipient caused by this organism i

227 9 infection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regim

228 cute liver failure in an adult hematopoietic stem cell transplant recipient.

229 omegalovirus encephalitis in a hematopoietic stem cell transplant recipient.

230 hich was similar to autologous hematopoietic stem cell transplant recipients (30.1%) and those who di

231 Autologous hematopoietic stem cell transplant recipients and those who do not dev

232 Hematopoietic stem cell transplant recipients are more likely to be im

233 Hematopoietic stem cell transplant recipients are more likely to devel

234 After a cluster of fatal toxoplasmosis among stem cell transplant recipients at 2 hospitals, surveill

235 the risk for MS in pediatric solid organ and stem cell transplant recipients by comparing them with m

236 ly 20% of pediatric allogeneic hematopoietic stem cell transplant recipients develop disseminated Ad

237 r subunit knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to g

238 rsus host disease treatment in hematopoietic stem cell transplant recipients often results in prolong

239 in preventing RSV LRTIs in 50 hematopoietic stem cell transplant recipients or patients with hematol

240 he effects of GvHD itself, all serve to make stem cell transplant recipients vulnerable to disease fr

241 frequency of severe sepsis in hematopoietic stem cell transplant recipients was five times higher wh

242 Twenty-four hematopoietic stem cell transplant recipients were enrolled sequential

243 nduction therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 rat

244 reata obtained at autopsy from hematopoietic stem cell transplant recipients who had received their t

245 rly, in subsequent admissions, hematopoietic stem cell transplant recipients with graft-versus-host d

246 We compared outcomes of hematopoietic stem cell transplant recipients with severe sepsis durin

247 A total of 21,898 hematopoietic stem cell transplant recipients with severe sepsis were

248 ected patients (renal transplant recipients, stem cell transplant recipients, and congenitally infect

249 ant women, neutropenic hosts, solid-organ or stem cell transplant recipients, and patients receiving

250 Upon adoptive transfer into hematopoietic stem cell transplant recipients, CAR-expressing lymphoid

251 has been successfully used in hematopoietic stem cell transplant recipients, its extension to the SO

252 eria included: infant ALL, relapsed ALL, and stem cell transplant recipients.

253 d mortality in solid organ and hematopoietic stem cell transplant recipients.

254 mortality of severe sepsis in hematopoietic stem cell transplant recipients.

255 Modification codes to identify hematopoietic stem cell transplant recipients.

256 f invasive aspergillosis among hematopoietic stem cell transplant recipients.

257 atological malignancies and in hematopoietic stem cell transplant recipients.

258 management of solid organ and hematopoietic stem cell transplant recipients.

259 eutic strategy for mucormycosis in organ and stem cell transplant recipients.

260 leading cause of mortality in hematopoietic stem cell transplant recipients.

261 mportant cause of morbidity and mortality in stem cell transplant recipients.

262 in older adults and autologous haemopoietic stem cell transplant recipients.

263 nd poor survival in allogeneic hematopoietic stem cell transplant recipients.

264 nd viral control in allogeneic hematopoietic stem cell transplant recipients.

265 ansplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 1

266 One-half of bone-marrow transplant (BMT) and stem-cell transplant recipients have reactivation of lat

267 ral maribavir in CMV-seropositive allogeneic stem-cell transplant recipients were evaluated in a rand

268 e reconstitution of autologous hematopoietic stem-cell transplant recipients with the progeny of matu

269 recent cohorts of solid-organ and allogeneic stem-cell transplant recipients, respectively.

270 d plasma specimens collected from allogeneic-stem-cell transplant recipients.

271 e 2b dose-range-finding prophylaxis study in stem-cell transplant recipients.

272 sease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex immune response

273 with JMML relies on allogeneic hematopoietic stem cell transplant, relapse is the most frequent cause

274 ion of stem cells from the BM and autologous stem cell transplant rescued RIL in mice.

275 chronic phase chronic myeloid leukemia with stem cell transplant reserved for patients who have dise

276 ine clinical factors, induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patien

277 r prevention and treatment of postallogeneic stem cell transplant (SCT) relapse.

278 The effects of stem cell transplant (SCT) status, underlying disease, a

279 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached.

280 se patients who relapse following autologous stem cell transplant (SCT), multiple treatment options a

281 cancer survivors who underwent myeloablative stem cell transplant (SCT).

282 e (p < 0.0001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor ov

283 Stem-cell transplant (SCT) was compared with chemotherap

284 eeding risk in patients receiving allogeneic stem cell transplants (SCTs) or chemotherapy but not in

285 host-reactive donor T cells from allogeneic stem-cell transplants (SCTs) using an anti-CD25 immunoto

286 Allogeneic stem cell transplant, the only treatment modality shown

287 Hematopoietic stem cell transplant therapy is limited by pulmonary inf

288 in cytotoxic anticancer therapies as well as stem cell transplant therapy.

289 RSV-B) outbreak in a hematology-oncology and stem cell transplant unit.

290 Allogeneic hematopoietic stem cell transplant was offered to selected patients in

291 Salvage high-dose chemotherapy plus a stem-cell transplant was required in six (6%) patients i

292 amustine-containing regimen, or haemopoietic stem-cell transplant were also excluded.

293 oma cells > or = 5,000/microL, or history of stem-cell transplant were ineligible.

294 y-one recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-enhanced MR ima

295 xty-five patients underwent nonmyeloablative stem cell transplant with ATG, TBI 200 cGy, and fludarab

296 skin biopsy in patients who have undergone a stem cell transplant with eruptions on the head and neck

297 sive detection of innate immune responses to stem cell transplants with magnetic resonance (MR) imagi

298 MSCs in vivo and can be used for tracking of stem cell transplants with MR imaging.

299 sive detection of innate immune responses to stem cell transplants with MR imaging.

300 were recipients of allogeneic hematopoietic stem cell transplant, with their infections caused by fi